BIOFILCHEM · Biofil Chemicals & Pharmaceuticals Ltd · Biotechnology & Drugs
BIOFILCHEM · Biofil Chemicals & Pharmaceuticals Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
34.8% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹12 Cr
Revenue YoY
PAT YoY
-95.4%
Operating margin
Revenue, last 5 quarters
P/E (TTM)
P/B
2.2
P/S (TTM)
Not available from data source
Sector P/E
Not available from data source
Dividend yield
Not available from data source
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| BIOFILCHEM (this stock) | 173 | 2.2 | +1.4% | +2.2% | 0.14 | Not available from data source |
| Sun Pharmaceutical Industries | 36.6 | 5.3 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
| Divi's Laboratories * | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 75.8 | 20 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
* Net margin, ROE, D/E and dividend yield for these companies come from RedixFi fundamentals; the data vendor had no values for them.
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| BIOFILCHEM | 2026-08-27 | 3856 | 1 | STRONG | BULK |
| BIOFILCHEM | 2026-08-26 | 214869 | 2 | STRONG | BULK |
| BIOFILCHEM | 2026-08-25 | 306386 | 2 | STRONG | BULK |
| BIOFILCHEM | 2026-08-24 | 232325 | 2 | STRONG | BULK |
| BIOFILCHEM | 2026-06-12 | 161254 | 2 | STRONG | BULK |
| BIOFILCHEM | 2026-06-11 | 213789 | 2 | STRONG | BULK |
| BIOFILCHEM | 2026-06-10 | 158499 | 2 | STRONG | BULK |
| BIOFILCHEM | 2026-06-05 | 31767 | 1 | STRONG | BULK |
| BIOFILCHEM | 2026-06-04 | 54300 | 1 | STRONG | BULK |
| BIOFILCHEM | 2026-05-26 | 153373 | 1 | WEAK | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedBiofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) reported a corrected profit before tax of ₹101.49 lakh for FY2021-22, down from an initial reported ₹104.49 lakh due to a typographical error. The company did not face any defaults in loan repayments or regulatory penalties during the year. No significant legal disputes or compliance issues were noted, and the auditor provided an unmodified opinion on the financial statements. The company also did not meet the criteria for Corporate Social Responsibility (CSR) requirements. Key financial figures include total income and expenditure details, though specific numbers are not provided in the summary. The company has no subsidiaries, and no material non-compliance with stock exchange or regulatory requirements was reported. The Board of Directors affirmed adherence to remuneration policies and governance practices.
- Corrected profit before tax for FY2021-22 is ₹101.49 lakh due to a typographical error in the initial report.
- No defaults in loan repayments or regulatory penalties were reported during FY2021-22.
- The auditor provided an unmodified opinion on the financial statements for FY2021-22.
- The company did not meet CSR criteria and thus no CSR activities were mandated.
- No significant legal disputes or compliance issues were noted in the annual report.
Key takeaway: Biofil Chemicals & Pharmaceuticals Limited reported a corrected profit before tax of ₹101.49 lakh for FY2021-22, with no defaults or regulatory penalties, and an unmodified audit opinion, indicating stable financial reporting and compliance.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (3 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
3 occurrencesRecent (last 12 months)
The company was fined by NSE & BSE under Chapter-VII(A) of SEBI Master Circular No.HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 for non-compliance of Regulation 6(1) and 6(1A) of SEBI (LODR) Regulations.
Earlier (1-3 years ago)
The company received an advisory letter from NSE for non-compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding not having a functional website and not updating website content within 2 working days of changes.
Older (3+ years ago)
In the previous financial year 2020-2021, the National Stock Exchange of India Limited imposed a fine of Rs. 8,61,400 (including GST) for non-compliance with Regulation 17(1)(c) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The company partially deposited Rs. 5,36,900 under protest, and the fine was later waived upon the company's waiver application.
Routine disclosures
Internal Control Weakness
1 occurrenceRecent (last 12 months)
The auditor mentions that detecting fraud-related misstatements is more challenging due to potential collusion and override of internal controls, and highlights the need to evaluate the adequacy and effectiveness of internal financial controls as per the Companies Act, 2013.
Contingent Liability
4 occurrencesRecent (last 12 months)
The company has pending litigations comprising claims against it, as disclosed in Note 27 of the Annual Report 2025-26.
Earlier (1-3 years ago)
The company has pending litigations, primarily from commuters and regulators, but has not provided for or disclosed contingent liabilities for matters considered remote, based on internal legal assessment and advice.
The company has pending litigations, primarily from commuters and regulators, but has not provided for or disclosed contingent liabilities for matters considered remote, based on internal legal assessment and legal advice.
Older (3+ years ago)
The company has pending litigations, including claims by commuters and regulators, but has not provided for or disclosed contingent liabilities for matters considered remote, based on legal assessment that these litigations would not result in liabilities.
Related-Party Transaction
5 occurrencesRecent (last 12 months)
The company entered related party transactions with Cyano Pharma Private Limited, MID (India) Pharmaceuticals Private Limited, and Formoplast Private Limited during the year.
Earlier (1-3 years ago)
The company entered related party transactions with Cyano Pharma Private Limited, MID (India) Pharmaceuticals Private Limited, and Formoplast Private Limited during the year.
The company seeks shareholder approval for a material related party transaction with Cyano Pharma Private Limited, which may exceed INR 1,000 crore or 10% of annual consolidated turnover.
Older (3+ years ago)
The company has approved a material related party transaction with Cyano Pharma Private Limited.
The company may enter into transactions with CPPL that could exceed 10% of its annual consolidated turnover, requiring shareholder approval as per SEBI regulations.
Management & Board Governance
2 occurrencesEarlier (1-3 years ago)
Ramesh Shah, the former Chairman and Managing Director of Biofil Chemicals and Pharmaceuticals Limited, ceased his office on 11th March 2025 due to his sudden demise.
Older (3+ years ago)
An independent director resigned before the expiry of their tenure, and the director confirmed there are no unresolved issues or conflicts.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
0.87% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).